Therefore, EGFR is considered to be an excellent target for this disease, and the anti-EGFR monoclonal antibody cetuximab (CTX), although yielding only modest clinical activity in monotherapy, is the only targeted therapy approved for the treatment of SCCHN in patients with locally advanced tumors in association with radiotherapy and in patients with recurrent or metastatic disease in combination with cisplatin-based chemotherapy [22, 24–26]. The gene discussed is EGFR; the disease is metastatic neoplasm.